RUNX1 and acute myeloid leukemia: In an analysis of AML patients treated with intensive chemotherapy by Tang et al. [7], the complete remission rate was lower in 62 newly-diagnosed patients with RUNX1-mutated AML compared with 408 without the mutation (56.8% vs. 77.5%).